Cullinan Oncology/CGEM

$16.55

-0.71%
-
1D1W1MYTD1YMAX

About Cullinan Oncology

Cullinan Oncology, Inc. is a biopharmaceutical company. The Company is focused on creating standards of care for patients with cancer. The Company’s lead candidate, unpartnered program, CLN-619, is a monoclonal antibody designed to stabilize expression of MICA/B on the tumor cell surface to promote tumor cell lysis mediated by both cytotoxic innate and adaptive immune cells. The Company is evaluating CLN-978, is a CD19xCD3 T cell engager with extended serum half-life and, based on preclinical data, robust potency against target cells expressing low levels of CD19. The Company's Zipalertinib (CLN-081/TAS6417), is an orally available small-molecule, irreversible epidermal growth factor receptor (EGFR) inhibitor that is designed to selectively target cells expressing EGFR exon 20 (EGFRex20) insertion mutations with relative sparing of cells expressing wild-type EGFR. The Company’s other product candidates include CLN-049, CLN-418, and CLN-617.

Ticker

CGEM

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Nadim Ahmed

Employees

85

Headquarters

Cambridge, United States

CGEM Metrics

BasicAdvanced
$717.9M
Market cap
-
P/E ratio
-$3.70
EPS
-
Beta
-
Dividend rate
$717.9M
$19.68
$7.64
421.09K
17.066
-29.68%
-30.98%
-31.19%
1.576
1.582
-256.32%

What the Analysts think about CGEM

Analyst Ratings

Majority rating from 7 analysts.
Buy

Price Targets

Average projection from 6 analysts.
54.08% upside
High $34.00
Low $19.00
$16.55
Current price
$25.50
Average price target

CGEM Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-23.8M
-39.13%
Profit margin
0%
-

CGEM Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 43.83%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$1.42
-$0.82
-$0.91
-$0.54
-
Expected
-$0.98
-$0.97
-$0.92
-$0.96
-$0.95
Surprise
44.9%
-15.46%
-1.27%
-43.83%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Cullinan Oncology stock?

Cullinan Oncology (CGEM) has a market cap of $717.9M as of April 16, 2024.

What is the P/E ratio for Cullinan Oncology stock?

The price to earnings (P/E) ratio for Cullinan Oncology (CGEM) stock is 0 as of April 16, 2024.

Does Cullinan Oncology stock pay dividends?

No, Cullinan Oncology (CGEM) stock does not pay dividends to its shareholders as of April 16, 2024.

When is the next Cullinan Oncology dividend payment date?

Cullinan Oncology (CGEM) stock does not pay dividends to its shareholders.

What is the beta indicator for Cullinan Oncology?

Cullinan Oncology (CGEM) does not currently have a Beta indicator.

What is the Cullinan Oncology stock price target?

The target price for Cullinan Oncology (CGEM) stock is $25.5, which is 54.08% above the current price of $16.55. This is an average based on projections from 6 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Cullinan Oncology stock

Buy or sell Cullinan Oncology stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing